Mycobacterium tuberculosis Complex, Molecular Detection, PCR
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Each year, Mycobacterium tuberculosis accounts for nearly 2 million deaths and is responsible for 9 million newly diagnosed cases of tuberculosis worldwide. Mycobacterium tuberculosis is spread from person-to-person via respiratory transmission, and has the potential to become resistant to many or all of the antibiotics currently used if antimycobacterial treatment is not promptly initiated. Therefore, rapid and accurate detection of Mycobacterium tuberculosis in patient specimens is of clinical and public health importance.
Conventional culture methods can generally detect Mycobacterium tuberculosis in 2 to 3 weeks, although up to 8 weeks of incubation may be required in some instances. Developed at Mayo Clinic, this rapid PCR assay detects Mycobacterium tuberculosis complex DNA directly from respiratory specimens and other specimens without waiting for growth in culture and, therefore, the results are available the same day the specimen is received in the laboratory. The assay targets a unique sequence within the katG gene, which is present in members of the Mycobacterium tuberculosis complex. In addition, the assay can detect genotypic resistance to isoniazid mediated by mutations in the katG target, when present.
Rapid detection of Mycobacterium tuberculosis complex, preferred method
Diagnosis of tuberculosis, when used in conjunction with mycobacterial culture
A positive result indicates the presence of Mycobacterium tuberculosis complex DNA. Members of the Mycobacterium tuberculosis complex detected by this assay include Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis Bacillus Calmette-Guerin, Mycobacterium africanum, Mycobacterium canetti, and Mycobacterium microti. The other species within the Mycobacterium tuberculosis complex (Mycobacterium bovis subspecies caprae and Mycobacterium pinnepedi) should, in theory, be detected using the primer and probe sequences in this assay, but they have not been tested at this time. This assay method does not distinguish between the species of the Mycobacterium tuberculosis complex.
A negative result indicates the absence of detectable Mycobacterium tuberculosis complex DNA.
Isoniazid (INH) resistance mediated through a katG mutation will be reported when observed but lack of a katG mutation does not imply that the isolate is susceptible to INH. There are other genetic loci in addition to katG that can contribute to resistance for this drug.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test should always be performed in conjunction with mycobacterial culture.
This rapid PCR assay detects Mycobacterium tuberculosis complex nucleic acid and, therefore, does not distinguish between viable, disease-related organisms and nucleic acid persisting from prior infection. Test results should be correlated with patient symptoms and clinical presentation before a definitive diagnosis is made.
A negative result does not rule out the presence of Mycobacterium tuberculosis complex or active disease because the organism may be present at levels below the limit of detection for this assay.
This test has not been studied for use with specimens from patients being treated with antituberculous agents and, therefore, should not be used to determine bacteriologic cure or to monitor response to therapy. It is not known how long the PCR assay can remain positive following treatment for Mycobacterium tuberculosis.
The sensitivity of this test from stool is 80% and from formalin-fixed, paraffin-embedded tissue is 63%, therefore testing of a second specimen from these sources should be considered to increase sensitivity if the result from the first specimen is negative.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Iseman MD: A clinician’s guide to tuberculosis. Philadelphia, PA. Lippincott Williams & Wilkins, 2000
2. Centers for Disease Control and Prevention: Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Weekly Rep 2003;52(No. RR-11):1-88